UPEXI, INC.
For the period ended Jun 30, 2025. Filed Sep 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 24, 2025
UPXI$0.62-6.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| UPEXI, INC. | ||||
|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
| Year ended June 30, | ||||
| 2025 · 2024 | ||||
| Cash flows from operating activities | ||||
| Net loss from operations | $(13,684,209) | $(23,658,438) | ||
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: | ||||
| Depreciation and amortization | 757,758 | 3,678,786 | ||
| Unrealized (gain) loss on digital assets | (101,332) | - | ||
| Digital asset revenue | (985,009) | - | ||
| Gain on the sale of VitaMedica and income from discontinued operations | - | (1,948,538) | ||
| Loss on the sale of New England Technology | - | 1,737,326 | ||
| Amortization of loan costs | 30,462 | 115,787 | ||
| Amortization of consideration discount | - | 1,112,676 | ||
| Impairment of goodwill and intangible assets | - | 7,869,425 | ||
| Inventory write-off | 748,874 | 1,812,319 | ||
| Loss on impairment of building | - | 336,434 | ||
| Loss on sale of assets related to relocation of facility | - | 569,195 | ||
| Gain on sale of interactive offers | - | (237,670) | ||
| Loss on the disposal of assets | 10,743 | - | ||
| Bad debt reserve for Amazon receivable | 933,950 | - | ||
| Reduction of acquisition payable | (152,500) | - | ||
| Issuance of stock for services | 250,000 | - | ||
| Lease impairment (gain on settlement) | (269,994) | - | ||
| Change in deferred tax asset | - | (344,802) | ||
| Stock based compensation | 2,106,862 | 1,169,843 | ||
| Changes in assets and liabilities, net of acquired amounts | ||||
| Accounts receivable | (484,580) | 675,709 | ||
| Inventory | (470,188) | 2,651,252 | ||
| Prepaid expenses and other assets | 222,005 | 106,611 | ||
| Operating lease payable | 20,965 | 302,050 | ||
| Accounts payable and accrued liabilities | 2,865,251 | (944,020) | ||
| Deferred revenue | (222,100) | 101,305 | ||
| Net cash provided by operating activities - Continuing Operations | (8,423,042) | (4,894,750) | ||
| Net cash provided by (used in) operating activities - Discontinued Operations | - | 4,793,374 | ||
| Net cash provided by operating activities | (8,423,042) | (101,376) | ||
| Cash flows from investing activities | ||||
| Proceeds from the sale of the building, net | 4,005,516 | - | ||
| Proceeds from the sale of VitaMedica, Inc. | - | 2,100,000 | ||
| Proceeds from the sale of E-core | 2,000,000 | - | ||
| Proceeds from the sale of Interactive Offers, net of liabilities paid | - | 203,025 | ||
| Acquisition and sale of digital assets, net | (104,910,839) | - | ||
| Acquisition of Cygnet Online LLC, net | - | (539,348) | ||
| Acquisition of property and equipment | (387,760) | (932,565) | ||
| Net cash provided by (used in) investing activities - Continuing Operations | (99,293,083) | 831,112 | ||
| Net cash (used in) provided by investing activities - Discontinued Operations | - | (4,206,823) | ||
| Net cash provided by (used in) investing activities | (99,293,083) | (3,375,711) | ||
| Cash flows from financing activities | ||||
| Payment on acquisition notes payable | (66,655) | (246,761) | ||
| Payment on convertible note | (150,000) | - | ||
| Proceeds from issuance of short-term debt | 20,000,000 | - | ||
| Proceeds from warrant exercise | 250,000 | - | ||
| Proceeds from issuance of stock | 92,556,053 | - | ||
| Issuance of preferred stock series A | 325,000 | - | ||
| Repayment of related party advance | (175,000) | - | ||
| Proceeds from related party advance | 75,000 | 100,000 | ||
| Proceeds from issuance of convertible notes | 350,000 | - | ||
| Repayment of related party note payable | (500,000) | - | ||
| Repayment on note payable on building | (2,634,538) | (207,028) | ||
| Net cash used in financing activities - Continuing Operations | 110,029,860 | (353,789) | ||
| Net cash (used in) provided by financing activities - Discontinued Operations | - | - | ||
| Net cash used in financing activities | 110,029,860 | (353,789) | ||
| Net increase (decrease) in cash - Continuing Operations | 2,313,735 | (4,417,427) | ||
| Net (decrease) increase in cash - Discontinued Operations | - | 586,551 | ||
| Cash, beginning of period | 661,415 | 4,492,291 | ||
| Cash, end of period | $2,975,150 | $661,415 | ||
| Supplemental Cash Flow Disclosures | ||||
| Interest paid | $805,880 | $839,000 | ||
| Income tax paid | $ | - | $ | - |
| Non-cash Investing and Financing Activities | ||||
| Issuance of common stock for acquisition of Cygnet | $ | - | $162,727 | |
| Non-cash proceeds in the sale of VitaMedica | $ | - | $1,900,000 | |
| Issuance of common stock for the repayment of convertible notes payable | $1,750,000 | $500,000 | ||
| Issuance of debt for acquisition of Cygnet | $ | - | $300,000 | |
| Bloomios non-cash payment of receivables, net | $ | - | $845,443 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.